EBS vs GALT: stock comparison and AI forecast
Emergent Biosolutions Inc. (EBS) and Galectin Therapeutics Inc (GALT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
EBS Emergent Biosolutions Inc.
- Market Cap
- $320M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
GALT Galectin Therapeutics Inc
- Market Cap
- $336M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- EBS and GALT have similar market capitalizations ($320M and $336M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | EBS | GALT |
|---|---|---|
| Market Cap | $320M | $336M |
| P/B Ratio | 1.02x | – |
| EPS | $-3.97 | $-0.50 |
| Book Value/Share | $6.11 | – |
| Revenue/Share | $12.66 | – |
| FCF/Share | $3.67 | – |
Profitability & Margins
| Metric | EBS | GALT |
|---|---|---|
| ROE | -83.2% | – |
| ROA | -26.2% | -187.8% |
| ROIC | -20.6% | 11.4% |
| Gross Margin | 48.4% | – |
| Operating Margin | -27.7% | – |
| Net Margin | -40.2% | – |
| EBT Margin | -37.0% | – |
| Tax Rate | -8.6% | – |
Financial Health
| Metric | EBS | GALT |
|---|---|---|
| Current Ratio | 4.58x | 0.10x |
| Quick Ratio | 2.27x | – |
| D/E Ratio | 2.18x | – |
| Financial Leverage | 3.18x | – |
| Interest Coverage | -1.3x | -9.2x |
| Working Capital | $436M | -$137M |
Cash Flow
| Metric | EBS | GALT |
|---|---|---|
| Operating Cash Flow | $200M | -$16M |
| Free Cash Flow | $188M | – |
| Capital Spending | -$12M | – |
| OCF Growth YoY | 1439.2% | – |
| FCF Growth YoY | 13357.1% | – |
| FCF/Sales | 29.0% | – |
| CapEx/Sales | 1.8% | – |
Operational Efficiency
| Metric | EBS | GALT |
|---|---|---|
| Asset Turnover | 0.65x | – |
| Receivables Turnover | 8.4x | – |
| Inventory Turnover | 1.2x | – |
| Fixed Assets Turnover | 3.7x | – |
| Days Sales Outstanding | 44 days | – |
| Days Inventory | 306 days | – |
| Payables Period | 57 days | – |
| Cash Conversion Cycle | 293 days | – |
Income Statement
| Metric | EBS | GALT |
|---|---|---|
| Total Revenue | $649M | – |
| Operating Income | -$180M | -$16M |
| Net Income | -$261M | -$28M |
| R&D Expense | $41M | $9M |
| SG&A Expense | $189M | – |
| Cost of Goods Sold | $335M | – |
Dividend & Shareholder Information
| Metric | EBS | GALT |
|---|---|---|
| Shares Outstanding | 51M | 101M |
| Net Income Growth | -443.5% | – |
| EPS Growth | -730.2% | – |
EBS vs GALT: stock comparison and AI forecast
Which is bigger, EBS or GALT?
EBS and GALT have similar market capitalizations ($320M and $336M).
Which one does Intratio's AI model rank higher, EBS or GALT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.